GlassScriptPhysician profile
Gregory F Lakin
NPI 1003867953
$10,073.81
in general payments reported to CMS, 2019-2025
18 companies · $8,828 in 2025
The $8,828 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $112 · 2021: $471 · 2022: $172 · 2023: $97.15 · 2024: $25.04 · 2025: $8,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,213 · Travel and Lodging: $601 · Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,212.50 |
| Travel and Lodging | $600.97 |
| Food and Beverage | $136.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $8,813.47 | 2025 | |
| Alkermes, INC. | $473.19 | 2019-2024 | Vivitrol, Vivitrol |
| Neurocrine Biosciences, INC. | $261.74 | 2019-2022 | |
| Eisai INC. | $133.23 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $124.97 | 2021 | |
| Jazz Pharmaceuticals INC. | $111.63 | 2020 | |
| Hikma Pharmaceuticals USA | $35.00 | 2022 | |
| Inspire Medical Systems, INC. | $27.75 | 2023 | Inspire |
| Abbvie INC. | $24.33 | 2021 | |
| Amgen INC. | $16.86 | 2019 | |
| Indivior INC. | $14.88 | 2019 | |
| Braeburn INC. | $14.08 | 2025 | Brixadi |
| Novo Nordisk INC | $11.64 | 2019 | |
| Orexo US, INC. | $11.04 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Lakin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.